Empagliflozin in Heart Failure Dialysis Patients

Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients

Empagliflozin is not still approved for glomerular filtration rate < 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Inclusion Criteria:

• Heart failure on dialysis with residual renal function

Exclusion Criteria:

• Dialysis patients with no residual urine